Journal of Pharmacokinetics & Experimental Therapeutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Opinion   
  • J Pharmacokinet Exp Ther 7:185,
  • DOI: 10.4172/jpet.1000185

Understanding the Pharmacokinetic Profile of Fluticasone: Implications for Therapeutic Efficacy and Safety

Zung Zang*
Department of Pharmaceutical Chemistry, Ninang Institute of Pharmacy, Japan
*Corresponding Author : Zung Zang, Department of Pharmaceutical Chemistry, Ninang Institute of Pharmacy, Japan, Email: zung.zang@gmail.jp

Received Date: Jun 01, 2023 / Published Date: Jun 29, 2023

Abstract

Fluticasone is a widely used corticosteroid medication with potent anti-inflammatory properties, primarily used in the treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). As with any medication, a thorough understanding of its pharmacokinetic profile is crucial to ensure optimal therapeutic efficacy and minimize the risk of adverse effects. This review aims to provide a comprehensive overview of the pharmacokinetics of fluticasone, including its absorption, distribution, metabolism, and elimination. Fluticasone exhibits high oral bioavailability, with minimal first-pass metabolism, when administered orally. However, it is predominantly administered via inhalation, which allows for targeted drug delivery to the lungs while minimizing systemic exposure. Upon inhalation, fluticasone is rapidly absorbed from the respiratory tract and undergoes extensive first-pass metabolism in the liver, primarily mediated by cytochrome P450 enzymes. The resulting metabolites are largely inactive and undergo further metabolism before elimination. The distribution of fluticasone is primarily limited to the tissues within the respiratory tract, where it exerts its anti-inflammatory effects. Minimal systemic distribution occurs due to its extensive hepatic metabolism and high protein binding. Fluticasone is primarily eliminated through hepatic metabolism, with the majority of the drug and its metabolites excreted in the feces.

Citation: Zang Z (2023) Understanding the Pharmacokinetic Profile of Fluticasone: Implications for Therapeutic Efficacy and Safety. J Pharmacokinet Exp Ther 7: 185. Doi: 10.4172/jpet.1000185

Copyright: © 2023 Zang Z. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top